Yüklüyor......
SUN-415 Panhypopituitarism: A Wake-Up Call in Patients Taking Anti-CTLA-4 Treatment
Background: Novel immune checkpoint proteins inhibitors, such cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) like ipilimumab could produce hypophysitis as a side effect with a prevalence between 0 to 10%. There are no guidelines in how to monitor patients receiving similar agents. We present a case...
Kaydedildi:
| Yayımlandı: | J Endocr Soc |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Endocrine Society
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553367/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-415 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|